Overview

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease
Phase:
Phase 1
Details
Lead Sponsor:
Seres Therapeutics, Inc.
Collaborator:
Memorial Sloan Kettering Cancer Center
Treatments:
Vancomycin